Aventisub

Aventisub is a key subsidiary of the global biopharmaceutical company Sanofi, primarily serving as a legal and intellectual property holding entity for its United States operations. The company was formed following the 2004 merger of Sanofi-Synthélabo and Aventis, inheriting a vast portfolio of established medicines and research programs. It is the registered owner of numerous patents and New Drug Applications (NDAs) for blockbuster products, including the insulin glargine brand Lantus and the anticoagulant Lovenox. Based in Bridgewater, New Jersey, Aventisub operates as an integral part of Sanofi's North American business unit. Its activities support Sanofi's broader mission in therapeutic areas such as immunology, neurology, oncology, and rare diseases. As a subsidiary, its financial and clinical performance is consolidated within the parent company's global reporting.